drugset / Trial / NCT01059643

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643

Phase 2 Completed 103 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.

Timeline

Start
2011-04
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject litronesib Small molecule 5 mg/m2 Intravenous
Subject litronesib Small molecule 6 mg/m2 Intravenous
Background Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous